Nerve growth factor variant conducive to expression, and use thereof
WO2026113060A1PCT designated stage Publication Date: 2026-06-04JIANGSU KANION PHARMA CO LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- JIANGSU KANION PHARMA CO LTD
- Filing Date
- 2024-12-10
- Publication Date
- 2026-06-04
Smart Images
Figure CN2024138287_04062026_PF_FP_ABST
Abstract
Provided is a nerve growth factor variant protein having the amino acid sequence set forth in SEQ ID NO. 1. Also provided is a medicament comprising the nerve growth factor variant protein for use in treating diabetic peripheral neuropathy, diabetic foot ulcer, and erectile dysfunction caused by diabetes.
Need to check novelty before this filing date? Find Prior Art